Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Transdermal Delivery of PTEN mRNA via HA-LNPs for Melanoma T

    2026-06-08

    Transdermal Delivery of PTEN mRNA via HA-LNPs for Melanoma Therapy

    Study Background and Research Question

    Melanoma remains one of the most aggressive and treatment-resistant forms of skin cancer, characterized by rapid proliferation and high metastatic potential. Despite advances in immunotherapy, including immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4, fewer than half of patients achieve lasting clinical benefit due to tumor resistance and immune evasion mechanisms. The phosphatase and tensin homolog (PTEN) gene is a crucial tumor suppressor that regulates the PI3K/Akt signaling pathway, constraining cell proliferation and promoting apoptosis. Loss or mutation of PTEN is common in melanoma and other malignancies, leading to unchecked tumor growth, impaired immune cell infiltration, and resistance to immunotherapies. Thus, restoring PTEN expression is a high-priority strategy for cancer research and gene therapy, with the goal of reactivating antitumor immunity and suppressing tumor progression (reference study).

    Key Innovation from the Reference Study

    The highlighted study introduces a novel, non-invasive transdermal approach for delivering tumor suppressor gene mRNA directly to melanoma sites using hyaluronate-conjugated lipid nanoparticles (HA-LNPs). Unlike traditional gene-replacement strategies relying on viral vectors or DNA constructs—which carry risks of genomic integration and persistent immunogenicity—this method leverages mRNA encapsulation for transient, cytoplasmic expression of PTEN. The innovation centers on the use of HA-dimyristoyl glycerol (HA-DMG) as a scalable, amphiphilic lipid conjugate that integrates hyaluronate directly into the LNP bilayer during self-assembly. This design eliminates the need for post-formulation surface modifications and replaces poly(ethylene glycol) (PEG), thereby reducing the risk of anaphylaxis and enhancing biocompatibility. HA moieties on the nanoparticle surface facilitate skin penetration and selective targeting of CD44-expressing melanoma cells, offering a clinically relevant and targeted platform for mRNA-based immunotherapy (reference study).

    Methods and Experimental Design Insights

    The researchers synthesized HA-DMG and incorporated it into the lipid nanoparticle formulation, enabling direct integration of hyaluronate into the LNP core. This self-assembly process yields HA-LNPs capable of stably encapsulating large mRNA payloads, such as PTEN mRNA. The nanoparticles exhibit favorable colloidal stability, enhanced uniformity, and improved biocompatibility relative to PEGylated LNPs. The in vitro experiments utilized melanoma cell lines to assess delivery efficiency, PTEN expression restoration, and downstream effects on cell viability and immunogenic cell death (ICD). For in vivo evaluation, the HA-LNPs were topically applied to melanoma-bearing mouse models. The researchers monitored parameters including skin and tumor penetration, PTEN protein expression, tumor growth inhibition, immune activation, and toxicity profiles.

    Protocol Parameters

    • HA-LNP formulation: Incorporate HA-DMG during lipid nanoparticle self-assembly to ensure stable hyaluronate display and avoid PEG-lipids.
    • mRNA encapsulation: Encapsulate in vitro transcribed, chemically modified PTEN mRNA at concentrations sufficient for robust gene expression in target cells.
    • Transdermal application: Apply HA-LNPs topically to the tumor site in animal models, allowing for deep skin and tumor penetration.
    • Readouts: Assess PTEN restoration, cell viability, immunogenic cell death markers, tumor volume, and immune cell infiltration post-treatment.

    Core Findings and Why They Matter

    The study finds that HA-LNPs efficiently encapsulate and deliver PTEN mRNA through the skin, selectively targeting CD44-positive melanoma cells. In vitro, the delivery system restored PTEN expression, induced immunogenic cell death, and significantly reduced melanoma cell survival. In vivo, topical application of PTEN mRNA-loaded HA-LNPs led to deep tumor penetration, marked tumor growth inhibition, and enhanced immune activation, with negligible toxicity observed in treated animals. These findings demonstrate that HA-LNP-mediated mRNA transfection and expression can overcome major challenges in cancer immunotherapy, such as poor cytosolic delivery, off-target effects, and immune resistance. The approach offers a non-integrating, transient, and tunable method for restoring tumor suppressor function in situ, with the potential for localized, repeated administration (reference study).

    Comparison with Existing Internal Articles

    Several internal resources offer complementary perspectives on the use of in vitro transcribed PTEN mRNA for cancer research and gene therapy:

    These resources collectively support the view that combining chemically optimized mRNA (e.g., Cap 1, poly(A) tail) with advanced nanoparticle delivery systems addresses key barriers in gene therapy research, particularly for challenging targets like melanoma.

    Limitations and Transferability

    While the HA-LNP platform demonstrates robust PTEN mRNA delivery and antitumor effects in preclinical melanoma models, several limitations should be considered. First, the study's findings are primarily validated in murine systems; translation to human clinical settings will require further investigation of pharmacokinetics, immune response, and long-term safety. The specificity of CD44-mediated targeting is promising for skin cancers but may require adaptation for other tumor types with different microenvironmental features. Additionally, the transient nature of mRNA-based interventions necessitates repeat dosing, and the scalability of HA-DMG synthesis must be validated for larger-scale or clinical applications. Despite these challenges, the approach represents a significant advance in mRNA delivery and tumor suppressor gene restoration, with potential applicability to other gene targets and delivery contexts.

    Research Support Resources

    For researchers interested in recapitulating or expanding upon these workflows, high-quality in vitro transcribed PTEN mRNA with enhanced capping and stability features is essential. EZ Cap™ Human PTEN mRNA (SKU R1025) provides a Cap 1-structured, poly(A)-tailed mRNA product suitable for advanced delivery systems such as HA-LNPs. This reagent is designed to maximize translation efficiency and minimize innate immune activation, aligning with the requirements demonstrated in the reference study. Protocol guidance and application notes are available through internal resources to support mRNA transfection, expression analysis, and workflow optimization in cancer research and gene therapy models.